Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Conditions: Cancer; Cancer, Lung; Cancer of Lung; Mesothelioma; Mesothelioma; Lung; Mesothelioma; Pleura; Mesotheliomas Pleural Interventions: Biological: UV1 vaccine + leukine; Biological: ipilimumab; Biological: nivolumab Sponsors: Åslaug Helland; Oslo University Hospital; Ultimovacs ASA; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Hospitals | Mesothelioma | Research | Vaccines | Yervoy